Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.42 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2729079 | 1.00 | PBRM1 (0.42) | PBRM1S100A4PTPRCMAPK1CYP1A2 | |
| SCHEMBL6669536 | 0.85 | PBRM1 (0.46) | PBRM1S100A4PTPRCMAPK1CYP1A2 | |
| SCHEMBL30512948 | 0.80 | PBRM1 (0.39) | PBRM1S100A4PTPRCMAPK1CYP1A2 | |
| SCHEMBL30512991 | 0.80 | PBRM1 (0.39) | PBRM1S100A4PTPRCMAPK1CYP1A2 | |
| SCHEMBL25409903 | 0.80 | PBRM1 (0.39) | PBRM1S100A4PTPRCMAPK1CYP1A2 | |
| SCHEMBL25411311 | 0.80 | PBRM1 (0.39) | PBRM1S100A4PTPRCMAPK1CYP1A2 | |
| SCHEMBL25409901 | 0.80 | PBRM1 (0.39) | PBRM1S100A4PTPRCMAPK1CYP1A2 | |
| SCHEMBL86917 | 0.79 | S100A4 (0.42) | PBRM1S100A4PTPRCMAPK1CYP1A2 | |
| SCHEMBL25261284 | 0.78 | TYMS (0.42) | S100A4AKT1ARCA1CA2 | |
| SCHEMBL20354665 | 0.78 | MAOB (0.40) | AKT1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119039221-A | Synthesis method of roflumilast | 沈阳药科大学 | 2024-11-29 | — | — | CN | claimed |
| CN-116891448-A | Preparation method of roflumilast intermediate III | 上海医药集团青岛国风药业股份有限公司 | 2023-10-17 | — | — | CN | claimed |
| US-20260146037-A1 | PEPTIDYL NITRILE COMPOUND AND USE THEREOF | SHANGHAI YIDIAN PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTD (CN) | 2026-05-28 | — | — | US | disclosed |
| CN-119751392-A | Benzofuran compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof | 南方医科大学 | 2025-04-04 | — | — | CN | disclosed |
| US-20250101011-A1 | PEPTIDYL NITRILE COMPOUND AND USE THEREOF | SHANGHAI YIDIAN PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTD (CN) | 2025-03-27 | — | — | US | disclosed |
| WO-2025001086-A1 | SYNTHESIS METHOD FOR ROXADUSTAT INTERMEDIATE | 江苏海洋大学 | 2025-01-02 | — | — | WO | disclosed |
| CN-119039221-A | Synthesis method of roflumilast | 沈阳药科大学 | 2024-11-29 | — | — | CN | disclosed |
| EP-4450497-A1 | PEPTIDYL NITRILE COMPOUND AND USE THEREOF | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd (CN) | 2024-10-23 | — | — | EP | disclosed |
| CN-118475575-A | Peptidyl nitrile compound and application thereof | 上海壹典医药科技开发有限公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-116803986-B | Synthesis method of roflumilast intermediate | 江苏海洋大学 | 2024-02-06 | — | — | CN | disclosed |
| CN-116891448-A | Preparation method of roflumilast intermediate III | 上海医药集团青岛国风药业股份有限公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-116803986-A | Synthesis method of roflumilast intermediate | 江苏海洋大学 | 2023-09-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101011-A1 | PEPTIDYL NITRILE COMPOUND AND USE THEREOF | CTSC, CTSL, CTRL | PBRM1 4442/4885S100A4 1228/4885PTPRC 1007/4885 |
| US-20260146037-A1 | PEPTIDYL NITRILE COMPOUND AND USE THEREOF | JAK1, CTSZ, CTSL | PBRM1 3525/4885S100A4 893/4885PTPRC 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.